need for a forum isolated from prying ears, for the informal discussion of medical problems across the specialties. This eliminates the need for impersonal, cumbersome, and inefficient referral forms or letters on often trivial problems, with a consequent saving of time for inpatients, more rapid institution of their treatment, and improved interdepartmental relations and co-operationsomething that cannot be valued in strictly economic terms. These results are significantly different at the 5% level using the corrected x2 test and it would therefore be difficult to convince any paediatric surgeon or radiotherapist in Melbourne that a controlled trial was ethically defensible.
There is one obvious difference between Birmingham and Melbourne in the method of dealing with such cases. While in Birmingham actinomycin D is given only when the diagnosis has been confirmed at operation, in Melbourne the drug is started as soon as there is a high index of suspicionusually on the evidence of an aortogram or inferior vena cavagram-with operation following on the t-hird day. All aibdominal masses in children are treated as emergencies, and handling of the child is kept to a minimum. This policy is rendered easier by the centralization of paediatric and radiotherapy services.-I am, etc.,
T. F. SANDEMAN
Melbourne, Australia 1 Sandeman, T. F., Australasian Radiology, 1970, 14, 285. Efficacy of Whooping-cough Vaccines SIR,-A recent report of the Public Health Laboratory Service (3 February, p. 259) showed that the pertussis vaccines produced by two manufacturers, whose names were published, gave significantly different levels of protection in children. I feel, therefore, that I can now disclose the identities of some vaccines which we have tested here in Manchester over the past 10 years but which were given only code letters in the papers previously submitted to you for publication.
The P.H.L.S. report showed that vaccines produced by Wellcome Laboratories were more effective than those of Glaxo Laboratories but that the vaccines concerned were made more than and, for some children in the survey, much more than-six years ago. The findings justify my own misgivings at that time'-3 about vaccines made before 1967. Pertussis agglutinogens 1, 2, and 3 were all present in Weilcome vaccines (designated 0)1 but agglutinogen 3 was not detected in Glaxo vaccines (A and R).12 Indeed, in referring to the Glaxo product of that time I said3 that it was "unlikely that such vaccines would give satisfactory immrunity against prevalent strains" of type 1, 3. The si-tuation since then is very different. Of vaccines made in 1967 the Glaxo product (vaccine X)4 gave an even better respon.se to agglutinogen 3, in both children and rabbits, than did the Wellcome product (vaccine Y); and a similar excellent response has been found with vaccine made in 1970. It would therefore not be in accordance with the available evidence if those administering pertussis vaccine to children were to think that recent Glaxo vaccine was sitill inferior to Wellcomne vaccine. Indeed, these results support our optimistic view of the future efficacy of British pertussis vaccines,5 which was based on the improved protection given to children by vaccines made during and after 1967.
Unfortunately for those who wish to ensure that suitable laboratory tests are used to monitor the protective potency of batches of pertussis vaccine this recen-t improvement in the efficacy of British vaccine has been accompanied by four changes that were all introduced at about the same time.6 In addition to the inclusion of detectable amounts of agglutinogen 3, mentioned above, the minimal acceptable mouse-protective potency of British vaccine has been raised from two to four intemational units per human dose, adjuvant has been reintroduced, and the recommended schedule for the vaccination of children has been changed.
In Israel a similar improvement in the efficacy of pertussis vaccine has been noted,7 but with fewer accompanying changes. In that country the improvement dates from 1968, when the inclusion of agglutinogen 3 in their vaccine was ensured. The earlier vaccine, which gave unsatisfactory protection, did, however, contain adjuvant and it also achieved a mouse-protective potency of four international units per human dose.8 Moreover, the vaccination schedule in Israel has not been altered.
The one feature common to the improvements in British and Israeli vaccines is that their manufacturers now make deliberate attempts to ensure that their products contain enough agglutinogen 3. But ought our hopes for the wellbeing of vaccinated children to be based merely on the good-will of present well-informed staff, adequate though this proves to be at present? Or should we formulate requirements which would ensure that present knowledge is not forgotten?
To I would like to stress that I did not write my letter to extol the virtues of Mandrax (methaqualone and diphenhydramine). My comnplaint was of a communication I had received from the senior medical officer. I can assure Dr. Mathers that I am aware of the addictive qualities of Mandrax, and if he will refer to my letter again he will note that only a little over 1 % of my patients had been prescribed this drug, and all the recipients were of a mature age. I cannot ever remember prescribing the drug to a youngster -in fact I find it unusual for a teenager to come to me with a sleep problem, and when they do it is usually amitriptyline which they receive.
I completely reject the advice of Dr. Green that I should accept the S.M.O's communication "in the manner intended." I considered that the letter was unnecessary, and it is my interpretation, devoid of paranoia, that the "manner intended" could have had but one object, and that was to intimidate me, and I think that intimidation should be resisted. I The day has drawn to a close and bedtime has arrived. Rather than risk taking half a Mandrax to soothe me off to sleep I'm going to have a nice stiff whisky instead. Good health and good night.-I am, etc., C. G. BROWN Slough, Bucks I General Register Office, Pharmaceutical Yoursal, 1973, 210, 77. Behcetes Syndrome and Oral Fibrinolytic Therapy SIR,-We were interested to read the paper of Drs. T. Chajek and M. Fainaru (31 March, p. 782) and, by reference to a similar case, would like to support their observation that impaired fibrinolysis is an important factor in the pathogenesis of Behget's syndrome.
We have under our care a male patient now aged 32. For eight years he has had recurrent attacks of deep venous thrombosis and one episode of pulmonary embolism. During this time he has also suffered from recurrent mouth ulcers, scrotal ulcers, erythema-nodosum-like lesions, and superficial phlebitis. When referred to us he had lower inferior vena caval obstruction but there was no proteinuria, suggesting that the renal veins were not affected. For a few years he had been treated with intravenous heparin and oral anticoagulants. Though this had
